From CNN Money:
San Diego-based Sequenom, Inc. is best known for a prenatal test designed to detect Down syndrome, but its chief executive said this week that the company sees an even bigger opportunity in genetic testing for inherited diseases like autism, heart ailments, cystic fibrosis and birth defects.
Speaking at the annual Lazard Capital Markets health care conference, Harry Stylli said the market for testing for prenatal chromosomal disorders like Down syndrome could be $3 billion to $5 billion worldwide, but he expected the market for the other disorders to be bigger.
They would be detected through testing for tiny variations in the genetic code called single nucleotide polymorphisms, or “snips.” Stylli said that about 6 percent of all babies have a birth defect, and 30 percent of those are due to an inherited condition.
“There are many other things that you’d like to be able to test for,” Charles Cantor, Sequenom’s chief scientific officer, said in a telephone interview. “Down’s is the single most common fetal defect, but it’s the tip of the iceberg.”
Earlier posts start here.